drugset / Trial / NCT00640185

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00640185

Phase 2 Completed 160 enrolled AbbVie
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).

Timeline

Start
2008-03
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pozanicline Small molecule 40 mg Oral
Subject Pozanicline Small molecule 80 mg Oral